Numerai’s Amphastar Pharmaceuticals AMPH Stock Holding History

Numerai’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-34,006	Closed	-$986K	–	452
2025 Q1	$986K	Buy	+34,006	New	+$1.09M	0.19%	162

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Numerai's AMPH Position: Q2 2025 in Review

Numerai sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2025, closing a stake of 34,006 shares — an estimated $986K sold.

Numerai first reported a position in AMPH in Q1 2025 and held it in 1 quarter. The position peaked at $986K in Q1 2025. 245 funds tracked by Wall St. Rank hold AMPH as of Q2 2025.

Numerai reported no remaining Amphastar Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Numerai sold 34,006 Amphastar Pharmaceuticals shares in Q2 2025, an estimated $986K.
Numerai first reported a position in Amphastar Pharmaceuticals in Q1 2025 and held it in 1 quarter.
Numerai's Amphastar Pharmaceuticals position peaked at $986K in Q1 2025.
245 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2025.

Based on Numerai's 13F filing for Q2 2025, filed 14 Aug 2025.